All articles

Low-Dose Naltrexone (LDN) for Fibromyalgia: Dosing, Evidence, What to Expect

in pictures and a few words

What it is and why it matters

Naltrexone is a medicine that, for fibromyalgia, is taken in a very small dose. In fibromyalgia, the nervous system can amplify pain signals even when the tissues aren’t damaged.

  • Of all the conditions where it’s discussed, it’s best tested in fibromyalgia
  • It was tested in people: compared with a dummy pill

What the trial showed

In a small trial in women with fibromyalgia, pain fell more on the medicine than on a dummy pill.

  • Each participant took both the medicine and the dummy pill, in turn
  • The dose in the trial: 4.5 mg at bedtime
  • The effect is measurable, but it helps some people

How it works

The nervous system has special cells. When they stay switched on for long, pain signals can get stronger. A low dose of naltrexone calms these cells, and in people on it, inflammation substances in the blood went down.

Special cells switched onPain feels strongerThe medicine calms them

The dose is built up slowly

You start with a small dose at bedtime and raise it step by step.

  • The starting 1.5 mg is kept for 2–4 weeks
  • The dose is raised only if it’s well tolerated
Start: 1.5 mg at bedtime+1.5 mg every 1–2 weeksGoal: 4.5 mg a day

A special form is needed

A regular naltrexone tablet is 50 mg. You can’t get such a small dose from it, so the medicine is made separately in the right strength.

When to expect a benefit

The benefit is judged no earlier than 6–8 weeks on 4.5 mg.

  • Many notice the first changes after 2–4 weeks
  • Everyone responds differently
Reached 4.5 mgWait 6–8 weeksJudge the benefit

Important. If there’s no benefit after 8–12 weeks on 4.5 mg — discuss with your doctor whether to stop and what to do next.

What happens at the start

In the first 1–2 weeks you may have vivid dreams and find it harder to fall asleep.

  • This usually passes by day 10–14

The medicine is an add-on

In the study, the medicine added to the usual measures rather than replacing them.

  • Sleep
  • Movement and physical activity
  • Being able to cope with stress

Who should see a doctor first

Before starting, discuss the plan with your doctor.

  • Fibromyalgia is diagnosed by a doctor, not guessed from symptoms
  • If usual treatment helps little: movement, special psychotherapy, prescribed medicines
  • If you also have Hashimoto’s or another immune disease — discuss a shared plan

Important. Before starting, the doctor must rule out contraindications: taking any painkillers from the opioid group, and pregnancy.

In one sentence

In fibromyalgia, low-dose naltrexone is better tested than in other diseases: it may reduce pain if the dose is built up gradually and together with a doctor.

Frequently asked questions

The defining crossover RCT (Younger et al. 2013, n=31 women) used 4.5 mg at bedtime; pain fell by 28.8% versus 18.0% on placebo (p=0.016). Titration typically starts at 1.5 mg, increasing by 1.5 mg every 1–2 weeks as tolerated.

This is the only LDN indication with a direct positive RCT: a defining crossover trial (Younger 2013, PMID 23359310) and cytokine data (Parkitny 2017, PMID 28536359). Improvement is also described in newer observations — one patient over 2 years (Moser 2025) and a retrospective chronic-pain cohort (Aalto 2025). A larger 2024 RCT (Bruun, n=99, Lancet Rheumatol, PMID 38258677) using 6 mg did not confirm a pain benefit. By comparison, Hashimoto thyroiditis has no direct RCTs yet — only mechanistic rationale.

The Younger trial assessed effect over an 8-week period (crossover design, 4-week phases separated by washout). Many patients report early changes within 2–4 weeks; response is individual. Assess the effect no earlier than 6–8 weeks at the 4.5 mg target dose.

In the first 1–2 weeks, vivid dreams and difficulty falling asleep may occur; they usually resolve by day 10–14. The dose is raised by 1.5 mg every 1–2 weeks only as tolerated.

LDN is discussed with a confirmed fibromyalgia diagnosis (not self-diagnosis by symptoms) and insufficient response to standard first-line therapy: physical activity, cognitive behavioral therapy, and when indicated, duloxetine, pregabalin or milnacipran. Discuss any LDN plan with your treating physician before starting — contraindications (concurrent opioid use, pregnancy) must be excluded.

This is a documented overlap scenario: both conditions are treated with the same drug in the same dose range (1.5–4.5 mg), and the mechanism overlaps (TLR4 blockade, reduced IL-6 and TNF-α). A confirmed diagnosis of both conditions and physician supervision are required, not self-treatment for one indication hoping it covers the other.

Share
Follow on TelegramGet new articles, research updates and practical health tips
Читать на русскомЧитати українською

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions. Full disclaimer

Ready to Take Action?

A consultation starts where the article ends: your history, your labs, a plan for your case.

Book consultationAsk a question